Abstract 4279
Background
Conventional chemotherapy agents such as doxorubicinare not curative and new therapies for metastatic sarcomas are urgently needed. Apatinib (YN968D1) as a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2) has been widely used as monotherapy or combined treatments. We performed a retrospective study with stage IV sarcoma cohort to investigate the efficacy of Apatinib with or without chemotherapy.
Methods
The information of 74 sarcoma patients in stage IV treated in Tianjin Medical University Cancer Hospital was collected and approved by the Institutional Review Board. Of these patients, 15 patients underwent Apatinib + traditional chemotherapy (combined group), and 59 received Apatinib as monotherapy (control group).
Results
We recruited 74 patients in this trial from Sep. 2015 to Apr. 2019. In the combined group, 6 of 15 patients (40.0%) recorded as partial response (PR), 7 of 15 patients (46.7%) recorded as stable disease (SD) and 2 patients (13.3%) was progressive disease (PD). The control group showed that 9 patients experienced PR (15.3%), 25 patients (42.4%) was SD and 25 patients (42.4%) was PD. The ORR (40.00% versus 15.25%, P = 0.034) and the DCR (86.67% versus 57.63%, P = 0.037) in the combined group showed significant higher than that of the control group. The median PFS of the combined group and control groups was 7.6 months and 7.9 months (P = 0.410). The median OS of the combined group and control group was 12.9 months and 17.3 months, respectively (P = 0.826). The mPFS and mOS shown no significant difference might due to the shorter follow-up time and small case number. Common AEs in combined group included hypertension (n = 7, 46.67%), hand-foot syndrome (n = 7, 46.67%), proteinuria (n = 8, 53.33%), anorexia (n = 4, 26.67%), fatigue (n = 4, 26.67%), transaminase increased (n = 4, 26.67%), diarrhea (n = 7, 46.67%), and anemia (n = 8, 53.33%), which all happened more frequently than in control group. No grade 4 AEs occurred, but 3 patients (20%) suffered from grade 3 AEs, which were mainly hypertension, hand-foot syndrome and proteinuria.
Conclusions
Chemotherapy combined with apatinib significantly increases the response rate and shows manageable adverse events.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2504 - Inadequacy of current definition and staging system of Medication-Related Osteonecrosis of Jaw (MRONJ) released by AAOMS : a Computed Tomography study in 151 cancer and myeloma patients
Presenter: Vittorio Fusco
Session: Poster Display session 1
Resources:
Abstract
2459 - Does bevacizumab increase joint pain ? Preliminary results of BEVARTHRALGIA Study
Presenter: Vauleon Enora
Session: Poster Display session 1
Resources:
Abstract
4913 - Prostatic cancer androgen deprivation therapy and bone health in carcinoma prostate.
Presenter: Gouri Shankar Bhattacharyya
Session: Poster Display session 1
Resources:
Abstract
1352 - Patterns of care for patients with metastatic bone disease in solid tumors – a cross-sectional study (SAKK 95/16)
Presenter: Michael Mark
Session: Poster Display session 1
Resources:
Abstract
6002 - Infection-Related Mortality in Different Types of Cancers
Presenter: Mohamed Gouda
Session: Poster Display session 1
Resources:
Abstract
5643 - Survival Trends in Critically ill Oncology Patients: impact of patient’s eligibility to post-ICU chemotherapy
Presenter: Edith Borcoman
Session: Poster Display session 1
Resources:
Abstract
3097 - Development and validation of a multivariable prediction model for 6-month mortality in older cancer patients: the GeriAtrIc-Tumor Score of PrEdiction for Early Death (GAIT SPEED)
Presenter: Angeli Angeli
Session: Poster Display session 1
Resources:
Abstract
856 - A Longitudinal Tracking and Quantitative Assessment of Paclitaxel-Induced Peripheral Neurotoxicity
Presenter: Ayumu Matsuoka
Session: Poster Display session 1
Resources:
Abstract
1662 - Efficiency of controlled cryotherapy in prevention of chemotherapy induced peripheral neuropathy (CIPN)
Presenter: Trudi Schaper
Session: Poster Display session 1
Resources:
Abstract
2766 - The Validity of Evaluations for Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Presenter: Teppei Yamada
Session: Poster Display session 1
Resources:
Abstract